

AD _____

Award Number: W81XWH-04-1-0283

TITLE: Functional Analysis of BORIS, a Novel DNA Binding Protein

PRINCIPAL INVESTIGATOR: Paul Yaswen, Ph.D.

CONTRACTING ORGANIZATION: University of California
Berkeley, CA 94720

REPORT DATE: April 2008

TYPE OF REPORT: Final

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Approved for Public Release;
Distribution Unlimited

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

REPORT DOCUMENTATION PAGE				Form Approved OMB No. 0704-0188	
Public reporting burden for this collection of information is estimated to average 1 hour per response, including the time for reviewing instructions, searching existing data sources, gathering and maintaining the data needed, and completing and reviewing this collection of information. Send comments regarding this burden estimate or any other aspect of this collection of information, including suggestions for reducing this burden to Department of Defense, Washington Headquarters Services, Directorate for Information Operations and Reports (0704-0188), 1215 Jefferson Davis Highway, Suite 1204, Arlington, VA 22202-4302. Respondents should be aware that notwithstanding any other provision of law, no person shall be subject to any penalty for failing to comply with a collection of information if it does not display a currently valid OMB control number. PLEASE DO NOT RETURN YOUR FORM TO THE ABOVE ADDRESS.					
1. REPORT DATE (DD-MM-YYYY) 01-04-2008		2. REPORT TYPE Final		3. DATES COVERED (From - To) 1 MAR 2004 - 28 FEB 2008	
4. TITLE AND SUBTITLE Functionanl Analysis of BORIS, a Novel DNA Binding Protein				5a. CONTRACT NUMBER	
				5b. GRANT NUMBER W81XWH-04-1-0283	
				5c. PROGRAM ELEMENT NUMBER	
6. AUTHOR(S) Paul Yaswen, Ph.D. E-Mail: P_Yaswen@lbl.gov				5d. PROJECT NUMBER	
				5e. TASK NUMBER	
				5f. WORK UNIT NUMBER	
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) University of California Berkeley, CA 94720				8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012				10. SPONSOR/MONITOR'S ACRONYM(S)	
				11. SPONSOR/MONITOR'S REPORT NUMBER(S)	
12. DISTRIBUTION / AVAILABILITY STATEMENT Approved for Public Release; Distribution Unlimited					
13. SUPPLEMENTARY NOTES					
14. ABSTRACT Abstract on next page.					
15. SUBJECT TERMS No subject terms provided.					
16. SECURITY CLASSIFICATION OF:			17. LIMITATION OF ABSTRACT	18. NUMBER OF PAGES	19a. NAME OF RESPONSIBLE PERSON
a. REPORT U	b. ABSTRACT U	c. THIS PAGE U			USAMRMC
			UU	12	19b. TELEPHONE NUMBER (include area code)

ABSTRACT

BORIS (*CTCF*L) is a paralog of the gene encoding CTCF, a multifunctional DNA binding protein that utilizes different sets of zinc fingers to mediate distinct gene regulatory functions, including those involved in cell growth regulation. Unlike *CTCF*, the expression of *BORIS* is normally restricted to specific cells in testes (the only cells where *CTCF* is not expressed), where it may play a role in reprogramming the methylation pattern of male germ line DNA. To define the possible consequences of aberrant *BORIS* expression in human breast cancers, we have used a well-characterized human mammary epithelial cell (HMEC) culture model. Our results indicate that in most breast cancer cells, endogenous *BORIS* is unlikely to be expressed at sufficient levels to interfere with CTCF functions, and that *BORIS* expression alone is not an efficient immortalizing factor. However, under certain conditions *BORIS* may cooperate with other changes (e.g. p53 inactivation) to destabilize the genomes of the cells in which it is aberrantly expressed. *BORIS* expression may cause genomic instability through aberrant effects on centrosome duplication during the cell cycle, and through effects on the regulation of several key early growth response genes.

Table of Contents

Cover.....	1
SF 298.....	2
Table of Contents.....	3
Introduction.....	4
Body.....	4
Key Research Accomplishments.....	9
Reportable Outcomes.....	9
Conclusions.....	9
References.....	9
Appendices.....	n/a

INTRODUCTION

Recently, a new gene was mapped to the 20q13.2 region that is commonly amplified in cancers of the breast and other tissues. This gene, BORIS (Brother of the Regulator of Imprinted Sites), is a paralog of the gene encoding CTCF, a multifunctional DNA binding protein that utilizes different sets of zinc fingers to mediate distinct functions in regulation of gene expression (reviewed in [1]). These functions include context-dependent promoter repression or activation, creation of modular hormone-responsive gene silencers, and formation of enhancer blocking elements (insulators). Several lines of evidence suggest that ubiquitously expressed CTCF is a critical determinant of cell growth regulation.

Unlike CTCF, which is expressed ubiquitously, the expression of BORIS is normally restricted to specific cells in testes (the only cells where CTCF is not expressed), where it may play a role in reprogramming the methylation pattern of male germ line DNA [2]. BORIS encodes an 11-zinc finger domain functionally equivalent to that in CTCF, while being completely divergent at the amino- and carboxy-termini – domains that have recently been shown to be critical for CTCF's insulator function [3]. Based on the finding that BORIS maps to the 20q13.2 region frequently altered in many malignancies, various cancer cell lines were screened for BORIS expression. BORIS transcripts were found in substantial proportions of a wide variety of tumor cell types [4]. Using an extremely sensitive 2 step multiplex RT-PCR method, A. Lindblom et al., (Karolinska Hospital, Sweden) reported frequencies of BORIS expression of 80 and 88%, respectively, in 17 breast tumor cell lines and of 148 randomly selected primary breast cancer samples (A. Lindblom, unpublished). In contrast, the same team was unable to detect BORIS mRNA in any normal mammary tissues, or other normal somatic tissues. Based on these findings, and results indicating that BORIS protein can compete for CTCF binding sites in the *H19* imprinting control region, the globin FII insulator, and the *c-MYC* promoter, **we hypothesized that aberrant expression of BORIS may interfere with certain CTCF functions, thereby promoting cancer progression.**

To define the possible consequences of aberrant BORIS expression that may promote cancer progression in the human breast, we have been using a well-characterized human mammary epithelial cell (HMEC) culture model (reviewed in [5]). HMEC cultured from normal breast tissue display a finite life span, low or undetectable telomerase activity, and decreasing telomere length with passage [6]. HMEC can spontaneously overcome a first RB-mediated, non-telomere length dependent proliferative arrest (stasis), associated with down-regulation of p16 expression [7]. The resultant p53(+), p16(-) post-selection HMEC cease net proliferation when their mean terminal restriction fragment (TRF) length is ~5 kb. As cells approach this second proliferative barrier, telomere dysfunction is evidenced by the presence of widespread chromosomal aberrations, particularly telomeric fusions, and mitotic failures [8]. In the p53(+) cultures, most cells remain viably arrested at all phases of the cell cycle, a growth arrest termed *agonescence* [8]. When p53 is inactivated, populations display the massive cell death typical of crisis [9]. Rare p53(+) and p53(-) immortal HMEC lines have been obtained following exposure to chemical carcinogens, over-expression of *c-myc* or *ZNF217* oncogenes, and/or a dominant negative p53 genetic suppressor element, GSE22 [10-12]. Surprisingly, the newly immortal p53(+) lines initially show very low or undetectable telomerase activity and continue to divide with increasingly shortened mean TRF lengths. When the mean TRF length gets extremely short (<3 kb), growth becomes slow and heterogeneous. An extended process, termed *conversion*, ensues, during which telomerase activity and growth capacity gradually increase [13]. In contrast, newly immortal p53(-) lines quickly display telomerase activity [12]. Our studies indicate that overcoming telomerase repression and telomere dysfunction are rate-limiting factors in the malignant transformation of cultured HMEC. Once these barriers have been overcome, the resulting immortal lines can be induced to become growth factor- and anchorage-independent, as well as tumorigenic, by introduction of a variety of well-characterized oncogenes.

BODY

Task 1: Perform correlative studies of endogenous BORIS expression and DNA binding activity in HMEC at specific stages of immortal transformation. Our preliminary qualitative analysis of BORIS expression in HMEC, performed in collaboration with Dr. Sergei Vatinin in Dr. Victor Lobanenko's lab (NIAID, NIH), indicated that this gene was not expressed in finite lifespan cultures derived from normal tissues, but that it was expressed in some cultures immortalized after exposure to a known chemical carcinogen or to specific oncogenes (data not shown). These data suggested that activation of BORIS expression might have been a cause or a consequence of changes accompanying immortalization, and served as a basis for the experiments proposed in our DOD IDEA grant.

We developed a quantitative RT-PCR assay (**Fig.1**) in our own lab for more precise measurements of BORIS mRNA levels in cell lines exhibiting normal or elevated levels of the 20q13 chromosomal region. Sensitivity and amplification efficiency of the BORIS PCR reaction were determined by amplifying standard dilutions of a BORIS cDNA-containing plasmid. The amplification efficiency in the range of $\sim 1 \times 10^2$ to 1×10^7 copies was measured to be 100% ($R^2 = 0.9946$). Testes RNA was used as a positive control in all experiments, and was used as a reference of physiological levels of expression. Transduction of BJ fibroblasts with an adenovirus that confers BORIS expression under the control of the CMV immediate early promoter/enhancer (CMV IE) directed these cells to produce BORIS at a level that was over three million fold greater than that of testes, which demonstrated the large dynamic range of this qRT-PCR assay. BORIS mRNA levels were normalized to the internal control, TATA-Binding Protein (TBP), which was amplified in parallel for all experiments. The amplification of TBP in these reactions validated both the integrity and successful reverse transcription of the RNA. We have used this quantitative assay to measure BORIS mRNA levels in human breast tumor cell lines and primary tumors. Using this assay, we unexpectedly found no evidence of BORIS expression in any breast cancer-derived cell lines, including three (T47D, MDA-MD-231, and MDA-MB-453) that had previously been reported to express BORIS transcripts [4]. A moderate level of BORIS mRNA (mean Ct = 35.08) was detected, however, within the MDA-MB-435 cell line, which was formerly considered to be of breast origin, but is now regarded to be derived from melanoma [14]. In the MDA-MB-435 cell line, we found the normalized level of BORIS to be 9.39% of the level expressed in testes (Table 1).




Figure 1. Scheme depicting BORIS gene and predicted RT-PCR products using different primer pairs. The inset shows a plot of the linearity of the quantitative PCR conditions used.

The discordance between our findings and those of Vatolin and colleagues [4], who described BORIS as being substantially expressed in the majority of (seven of eight) breast cancer cell lines, caused us to further evaluate our methodology. Because the two studies used PCR assays that amplify different regions of the BORIS cDNA, we initially postulated that alternatively spliced transcripts existed that could account for the large discrepancy.

We therefore designed three additional pairs of RT-PCR primers that could detect the presence of possible alternatively spliced variants. Although we did identify a splice variant in testes, we were again unable to detect BORIS transcripts of any form in breast cell lines (0/12) or tumors (0/8) using quantitative RT-PCR assays. Similar negative results have recently been reported for a majority of prostate cell lines and tumors [15].

Since Dr. Vatolin has left the Lobanenko lab and no longer works on BORIS transcription, we can only speculate as to the reasons for the discrepancies in our respective results. It is worth noting, however, that the methods published in the Vatolin et al. paper [4] indicate that 40 to 45 cycles were used for the PCR amplification of BORIS transcripts. The use of such conditions might be expected to lead to the detection of very rare ($\ll 1$ transcript per cell) transcripts in the samples assayed.

The quantitative results indicated that the levels of BORIS gene expression in most human breast cell lines and primary tumors (< 1 transcript/cell) were unlikely to be sufficient to generate enough protein to interfere with CTCF function. The possibility remained, however, that there was discordance between BORIS mRNA and protein levels, and that BORIS transcripts at very low abundance were capable of generating significant

	Sample	20q13.2 Amplification*	PCR Amplicons (exon/exon)				qRT-PCR		
			10 / 11	2 / 11	2 / 6	6 / 10	Mean Ct		% testis
							10 / 11	TBP	
Cell Lines	MDA-MB-453	-	-	NA	-	-	Not Detect	26.86	0.00%
	MDA-MB-231	-	-	-	-	-	Not Detect	25.84	0.00%
	MCF-10A	-	-	NA	-	-	Not Detect	26.30	0.00%
	T47D	-	-	NA	-	-	Not Detect	26.83	0.00%
	MCF-12A	-	-	NA	-	-	Not Detect	26.69	0.00%
	MDA-MB-436	-	-	NA	-	-	Not Detect	27.26	0.43%
	MCF-7	+	-	-	-	-	Not Detect	25.83	0.00%
	SUM185PE	+	-	NA	-	-	Not Detect	26.73	0.00%
	UACC812	+	-	NA	-	-	Not Detect	26.70	0.00%
	AU565	+	-	NA	-	-	Not Detect	27.06	0.00%
	BT474	+	-	NA	-	-	Not Detect	26.35	0.00%
	SKBR3	+	-	NA	-	-	Not Detect	28.53	0.00%
	MDA-MB-435*	+	+	NA	+	+	35.08	28.20	9.39%
Breast Tumors	T686	NA	-	NA	-	-	Not Detect	28.57	0.00%
	T688	NA	-	NA	-	-	Not Detect	31.39	0.00%
	T689	NA	-	NA	-	-	Not Detect	28.82	0.00%
	T691	NA	-	NA	-	-	Not Detect	30.10	0.00%
	T693	NA	-	NA	-	-	Not Detect	27.86	0.00%
	T694	NA	-	NA	-	-	Not Detect	27.64	0.00%
	T695	NA	-	NA	-	-	Not Detect	29.72	0.00%
	T-Amb	NA	-	NA	-	-	Not Detect	29.95	0.00%
Normal Breast	N-Amb	NA	-	NA	-	-	Not Detect	29.89	0.00%
	N6N7	NA	NA	NA	-	-	NA	NA	NA
Controls	Water	NA	-	-	-	-	Not Detect	Not Detect	NA
	minus RT	NA	-	-	-	-	Not Detect	Not Detect	NA
	genomic DNA	NA	-	-	-	-	Not Detect	Not Detect	NA
	Testes	NA	+	+	+	+	27.49	24.03	100.00%
	BORIS plasmid	NA	+	+	+	+	18.42-35.32	NA	NA
	BJ Fibroblasts	NA	-	-	-	-	Not Detect	24.07	0.00%
	BJ + Adeno-BORIS	NA	+	+	+	+	13.09	24.62	3.2E6%

Table 1. Quantitative RT-PCR results using different primer pairs.

amounts of protein with long half-life. To date, efforts to generate specific anti-BORIS antibodies have been unsuccessful, with one exception [2] that is limited in quantity and unavailable to us. A commercially available anti-BORIS antibody (Abcam) has recently become available. We generated a recombinant adenovirus encoding an HA-tagged BORIS protein, and used MCF7 cells infected with this virus to test the commercial antibody. The antibody did detect a band of the predicted size (83 kD) on an immunoblot of BORIS-transduced cells, but not in untransduced MCF7 or MDA-MB-231 cells (data not shown). These protein results confirmed our qRT-PCR results and strengthened our conclusion that, despite the presence of the BORIS gene in the amplified region of 20q, endogenous BORIS was unlikely to be expressed at sufficient levels to interfere with CTCF functions in most breast cancer cells.

Task 2: Determine whether exogenous BORIS expression influences properties associated with conversion of p53(+) immortal HMEC. To address this problem, we introduced retroviruses containing BORIS cDNA or a control eGFP reporter gene into growing cultures of conditionally immortal 184A1 HMEC prior to conversion. Cell cultures were treated with selection agent G418. No significant differences in proliferation rate were noted between cells expressing the exogenously introduced BORIS gene and cells expressing the exogenously introduced eGFP reporter gene alone. We have therefore concluded that BORIS expression does not influence properties associated with conversion of p53(+) immortal HMEC.

Task 3: Determine whether exogenous BORIS expression extends the proliferative potential of, or immortalizes finite lifespan HMEC when expressed alone or in combination with oncogenes *c-MYC* or *ZNF217*, or a dominant negative p53 genetic suppressor element. We tested the oncogenic properties of BORIS in HMEC directly by transducing the gene alone or in combination with additional changes that may act cooperatively with it. We transduced growing cultures of post-selection 184 HMEC with BORIS or a control vector. To monitor BORIS expression, we used a vector that contains an eGFP reporter gene linked to the

BORIS gene by an internal ribosome entry site (IRES). The IRES sequence allows the translation of two proteins from a single transcript. Since BORIS is located 5' to the eGFP-coding region, all cells expressing eGFP green fluorescence are expected to also express high levels of BORIS protein. In each experiment, 3 plates of each condition were infected and monitored independently to control for jackpot effects and overgrowth by rare variants within a population. As shown in Fig.2, all three cell populations infected with the BORIS virus expressed very high levels of the transcript. In contrast, cells infected with the control vector did not show any expression of BORIS.



Figure 2. Expression of BORIS mRNA in 184 HMEC transduced with control vector (pCLXSN) or BORIS as determined by semi-quantitative RT-PCR. Expression of the housekeeping gene, GAPDH, was assayed as a control.

The transduced cells were monitored for population doubling times between subcultures, and morphological signs of agonescence or crisis. We did not observe any significant differences in cell morphology (Fig.3) or in growth rate (Fig. 4) initially after the infections. None of the cells transduced with BORIS showed detectable levels of hTERT prior to agonescence (Fig. 5). However, one (SEBORIS2) of the three cell cultures infected with the BORIS virus yielded a single clone that overcame agonescence and became immortal. Cells originating from this clone retained functional p53 and gradually reactivated hTERT expression (Fig. 5). We performed similar experiments in parallel, using finite lifespan pre-stasis HMEC and human fibroblasts derived from the same specimen. None of the cells transduced with BORIS immortalized in these latter experiments.




Figure 3. Morphology of post-selection 184 HMEC infected with (A) control, or (B) BORIS virus.




Figure 4. Growth rates of post-selection 184 HMEC infected with control (blue) or BORIS (red) containing viruses at passage 8 and grown until most cells stopped dividing.

Additional gene transfer experiments were performed using a second retroviral construct in which the BORIS gene was expressed as a fusion protein with eGFP at its C-terminus to directly track protein expression in real time. Cells transduced with this construct exhibited green fluorescence in the nuclei, as expected, whereas cells transduced with the control virus (containing the eGFP gene alone) showed fluorescent signal predominantly in the cytoplasm. Despite the high levels of BORIS-eGFP expressed by the cells in this experiment, no immortalization was observed.

Altogether, the above results suggest that BORIS alone is not an efficient immortalizing factor, but that under certain conditions it might cooperate with other unknown stochastic changes to immortalize normal finite lifespan cells. Aberrant BORIS expression may cooperate with other defects to enable cells to overcome agonescence and express telomerase. As one test of this hypothesis, we transduced growing cultures of post-selection HMEC with BORIS and/or the dominant negative p53 genetic suppressor element, GSE22. In this experiment, 3 plates of each condition were infected and monitored independently to control for jackpot effects and overgrowth by rare variants within a population. During the experiment, cells were monitored for morphological changes and population doubling times between subcultures, as well as signs of agonescence or crisis. In this experiment, we did not observe that cells infected with both BORIS and GSE22 had any advantage over the other cells in terms of growth rate. However, these cells demonstrated significant aberrations in cytokinesis, which were not detected in cells transduced with GSE22 alone (Fig.6). p53 is known to play a role in control of cell division check points, as well as in processes controlling centrosome maturation and amplification. It is possible that lack of functional p53 in concert with BORIS over-expression can affect centrosome duplication during the cell cycle, leading to hyper-amplification. Centrosome amplification (the presence of more than two centrosomes at mitosis) is




Figure 5. The levels of hTERT transcripts in 184 cells transduced with BORIS were analyzed by quantitative RT-PCR. The results were normalized to the expression of porfobilinogen deaminase – a constitutively expressed “housekeeping” gene.

characteristic of many human cancers. Extra centrosomes can cause the assembly of multipolar spindles, which unequally distribute chromosomes to daughter cells resulting in genetic imbalances. The cells of most late-stage human cancers are aneuploid, genomically unstable and show high incidence of centrosome amplification. Genomic instability is thought to be a major driving force in multiple-step carcinogenesis. We hypothesize that in cells where it is expressed at sufficient levels, BORIS can be one of the proteins involved in control of centrosome duplication during the cell cycle. In accordance with this hypothesis, we have found that, in addition to their nuclear localization, BORIS-eGFP fusion proteins sometimes co-localize with δ -tubulin, a specific marker of centrosomes (Fig.7A). HMEC cultures transfected with BORIS displayed higher percentages of cells with > 2 centrosomes than cultures transfected with control or GSE22 vectors alone, and these differences persisted with passage (Figs.7B & 8).




Figure 6. Morphology of 184 cells infected with: (A) BORIS/pBABE control; (B) pCLXSN control/pBABE control; (C) pCLXSN control/GSE22 (D) BORIS/GSE22. The arrows in panel D point to cells undergoing aberrant cytokinesis.




Fig. 7 A) Co-localization of BORIS-GFP and δ -tubulin in 184-GSE22 cells transfected with BORIS-GFP; B) Cells displaying abnormal numbers of δ -tubulin positive centrosomes in cultures transfected with GSE22 and BORIS (184-GSE-BORIS), transfected with BORIS alone (184-BORIS), or immortalized after p53 inactivation (184AA2). A representative cell displaying 2 centrosomes in a control culture (184) is shown for comparison. Arrows indicate cells with ≥ 3 centrosomes.




Figure 8. Quantitation of percentages of cells with > 2 centrosomes in 184 cells infected with: pCLXSN control/pBABE control (CB); pCLXSN control/GSE22 (CG); BORIS/pBABE (BB); BORIS/GSE22 (BG) retroviruses and assayed at passages (p) 10-12. Immortally transformed HMEC lines AA2 and B5Me were assayed for comparison.

Task 4: Determine whether exogenous BORIS expression influences additional phenotypic properties of normal or immortalized HMEC.

A) Anchorage dependence: Anchorage-independent growth (AIG) is often exhibited by cells derived from human breast tumors or by cells that have been tumorigenically transformed *in vitro*. To determine if BORIS is able to promote AIG we suspended retrovirally transduced immortal HMEC in 1.5% methylcellulose in growth medium. The BORIS expression level in cells used in the experiment was determined by semi-quantitative RT-PCR prior to plating. The cells were fed weekly and, at 4 weeks post-plating, the plates were visually inspected for the presence of cell colonies displaying AIG. No such colonies were detected in cultures of immortal HMEC

over-expressing BORIS (data not shown), suggesting that BORIS alone is not sufficient to confer this phenotype.

B) Gene expression: To determine whether BORIS directly or indirectly influences cellular transcription, we have performed expression microarray experiments using a new state-of-the-art Affymetrix HTA GeneChip system recently purchased by LBNL's Life Sciences Division. This high throughput facility presently employs U133A 2.0 chips of reduced feature size in a 96-well format. We transduced 184 HMEC with either BORIS or control retroviruses and harvested RNA after a brief selection. Microarray analysis was performed using duplicate samples, and the resulting data were analyzed using commercial GeneTraffic software (Stratagene). Genes which showed consistent differences of > 2 fold compared with controls were selected for further study. PCR primers were designed for several of these genes, and altered regulation was confirmed by semi-quantitative RT-PCR (Fig.9). Transient transfections were performed in 184 HMEC with increasing amounts of the BORIS-IRES-eGFP or control plasmids, and the harvested RNA subjected to quantitative RT-PCR to further document the dependence of selected gene transcripts on BORIS expression. The example shown in Fig.10 shows the direct correspondence between amount of BORIS plasmid transfected and ATF3 transcripts expressed. ATF3 is of particular interest because it is a member of the CREB protein family of transcription factors. In addition to ATF3, a number of early growth response genes, including the oncogenes Fos and Jun, appear to be significantly upregulated by BORIS expression. Also of interest is the up-regulation of ZNF165, which like




Figure 9. Semi-quantitative RT-PCR results for genes that showed differential expression in 184 HMEC transduced with BORIS vs. control retroviruses.




Figure 10. Transient transfections with increasing concentrations of BORIS-IRES-eGFP plasmid (0.5, 1, and 2 µg/60 mm dish) and empty vector at the same concentrations confirm that BORIS regulates ATF3 expression. The cells were harvested 24 hrs. after transfection with the indicated plasmids, and the levels of ATF3 mRNA were quantified by quantitative RT-PCR. The levels were then normalized using the levels of CTCF transcripts for normalization.

BORIS itself, has been reported to be a cancer-testis antigen.

Task 5: Determine whether interference with endogenous BORIS expression blocks growth and/or telomerase expression in immortalized HMEC. In light of the qRT-PCR results reported for Task 1, these experiments were aborted.

KEY RESEARCH ACCOMPLISHMENTS

- We have developed a quantitative RT-PCR assay for BORIS mRNA expression, and have determined that the levels of BORIS expressed in most human breast cancer cell lines and tumors are unlikely to be sufficient to compete with CTCF for binding to CTCF sites.
- Our results suggest that BORIS alone is not an efficient immortalizing factor, but that in rare instances it might cooperate with additional factors to induce immortalization.
- Cells infected with both BORIS and GSE22 (a dominant negative p53 genetic suppressor element) demonstrated significant aberrations in cytokinesis, which were not detected in cells transduced with GSE22 alone.

- In addition to their nuclear localization, BORIS-eGFP fusion proteins sometimes co-localized with δ -tubulin, a specific marker of centrosomes.
- HMEC cultures transfected with BORIS displayed higher percentages of cells with > 2 centrosomes than cultures transfected with control or GSE22 vectors alone, and these differences persisted with passage.
- Microarray and RT-PCR analyses have identified several key early growth response genes as well as a cancer-testis antigen gene whose regulation was altered by exogenous BORIS expression in HMEC.

REPORTABLE OUTCOMES

Yaswen, P., Mroczkowska, J.E., Stampfer, M., Pack, S.D., and Lobanenko, V.V., "Functional Analysis of BORIS, a Novel DNA-Binding Protein" poster presented at the DOD Era of Hope meeting, Philadelphia, PA (6/8/05-6/11/05).

Yaswen, P. "Functional Analysis of BORIS using Cultured Human Mammary Epithelial Cells" invited talk presented at 3rd Intl. Conference on CTCF/BORIS, Hilton Head, SC (5/8/06-5/10/06).

Hines, W.C., and Yaswen, P. A sensitive qRT-PCR assay indicates BORIS (CTCF) is not expressed in most human breast cancers and tumor-derived cell lines. Manuscript in preparation.

CONCLUSIONS

Our results to date indicate that despite its presence in the frequently amplified region of chromosome 20q, the BORIS gene is rarely expressed at significant levels in most human breast cancers, and therefore is unlikely to play a significant etiologic role in this disease. However, our results do indicate that in the rare cases where BORIS is aberrantly expressed, it may cooperate with other changes (e.g. p53 inactivation) to destabilize cellular genomes. Since BORIS-eGFP protein sometimes co-localizes with centrosomes, it is possible that BORIS expression can cause genomic instability through aberrant effects on centrosome duplication during the cell cycle. BORIS expression may also cause genomic instability through its significant effects on the regulation of several key early growth response genes.

REFERENCES

1. Ohlsson R, Renkawitz R, Lobanenko V: **CTCF is a uniquely versatile transcription regulator linked to epigenetics and disease.** *Trends Genet* 2001, 17(9):520-527.
2. Loukinov DI, Pugacheva E, Vatolin S, Pack SD, Moon H, Chernukhin I, Mannan P, Larsson E, Kanduri C, Vostrov AA *et al*: **BORIS, a novel male germ-line-specific protein associated with epigenetic reprogramming events, shares the same 11-zinc-finger domain with CTCF, the insulator protein involved in reading imprinting marks in the soma.** *Proc Natl Acad Sci U S A* 2002, 99(10):6806-6811.
3. Defossez PA, Gilson E: **The vertebrate protein CTCF functions as an insulator in *Saccharomyces cerevisiae*.** *Nucleic Acids Res* 2002, 30(23):5136-5141.
4. Vatolin S, Abdullaev Z, Pack SD, Flanagan PT, Custer M, Loukinov DI, Pugacheva E, Hong JA, Morse H, 3rd, Schrupp DS *et al*: **Conditional expression of the CTCF-paralogous transcriptional factor BORIS in normal cells results in demethylation and derepression of MAGE-A1 and reactivation of other cancer-testis genes.** *Cancer Res* 2005, 65(17):7751-7762.
5. Stampfer M, R., Yaswen P: **Culture models of human mammary epithelial cell transformation.** *J Mam Gland Bio Neo* 2000, 5:365-378.
6. Stampfer MR, Yaswen P: **Human epithelial cell immortalization as a step in carcinogenesis.** *Cancer Lett* 2003, 194(2):199-208.

7. Brenner AJ, Stampfer MR, Aldaz CM: **Increased p16INK4a expression with onset of senescence of human mammary epithelial cells and extended growth capacity with inactivation.** *Oncogene* 1998, 17:199-205.
8. Romanov S, Kozakiewicz K, Holst C, Stampfer MR, Haupt LM, Tlsty T: **Normal human mammary epithelial cells spontaneously escape senescence and acquire genomic changes.** *Nature* 2001, 409(6820):633-637.
9. Garbe JC, Holst CR, Bassett E, Tlsty T, Stampfer MR: **Inactivation of p53 function in cultured human mammary epithelial cells turns the telomere-length dependent senescence barrier from agonescence into crisis.** *Cell Cycle* 2007, 6(15):1927-1936.
10. Stampfer MR, Bartley JC: **Induction of transformation and continuous cell lines from normal human mammary epithelial cells after exposure to benzo(a)pyrene.** *Proc Natl Acad Sci USA* 1985, 82:2394-2398.
11. Nonet GH, Stampfer MR, Chin K, Gray JW, Collins CC, Yaswen P: **The ZNF217 gene amplified in breast cancers promotes immortalization of human mammary epithelial cells.** *Cancer Res* 2001, 61(4):1250-1254.
12. Stampfer MR, Garbe J, Nijjar T, Wigington D, Swisshelm K, Yaswen P: **Loss of p53 function accelerates acquisition of telomerase activity in indefinite lifespan human mammary epithelial cell lines.** *Oncogene* 2003, 22:5238-5251.
13. Stampfer MR, Bodnar A, Garbe J, Wong M, Pan A, Villeponteau B, Yaswen P: **Gradual phenotypic conversion associated with immortalization of cultured human mammary epithelial cells.** *Mol Biol Cell* 1997, 8:2391-2405.
14. Rae JM, Creighton CJ, Meck JM, Haddad BR, Johnson MD: **MDA-MB-435 cells are derived from M14 melanoma cells—a loss for breast cancer, but a boon for melanoma research.** *Breast Cancer Res Treat* 2007, 104(1):13-19.
15. Hoffmann MJ, Muller M, Engers R, Schulz WA: **Epigenetic control of CTCFL/BORIS and OCT4 expression in urogenital malignancies.** *Biochemical pharmacology* 2006, 72(11):1577-1588.